The treatment with both histone deacetylase inhibitors and morpholino modified antisense oligo upregulated the levels of SMN, indicating that SMA patient-derived urine cells may be used as a tool for molecular studies and for screening of potential compounds and drugs to treat SMA [27,28]. Here, SMN1 is linked to proximal spinal muscular atrophy.